Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : BioMed Central, [2001-
    • الموضوع:
      Patient Reported Outcome Measures* ; Quality of Life* ; Feasibility Studies* ; Lymphoma, Large B-Cell, Diffuse*/therapy ; Lymphoma, Large B-Cell, Diffuse*/immunology ; Lymphoma, Large B-Cell, Diffuse*/drug therapy ; Immunotherapy, Adoptive*/adverse effects ; Immunotherapy, Adoptive*/methods; Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Prospective Studies ; Young Adult ; Receptors, Chimeric Antigen/therapeutic use ; Receptors, Chimeric Antigen/immunology ; Receptors, Antigen, T-Cell/therapeutic use ; Receptors, Antigen, T-Cell/immunology ; Longitudinal Studies ; Neoplasm Recurrence, Local/immunology ; Treatment Outcome
    • نبذة مختصرة :
      Purpose: Chimeric antigen receptor T-cell (CART) therapy has shown clinical efficacy in refractory and relapsed large B-cell lymphomas, but is associated with serious acute and long-term toxicities. To understand the patient perspective, we measured a patient-reported outcome (PRO), specifically, health-related quality of life (HRQoL), at multiple time points over one year.
      Methods: This was a prospective feasibility study of a cohort of patients who were eligible for standard of care CART therapy, tisagenlecleucel. Demographic data and disease characteristics were collected. HRQoL was measured using FACT-Lym at baseline, and months 1, 3, 6 and 12. FACT-Lym includes FACT-G (physical, social, emotional and functional well-being domains), plus a lymphoma subscale.
      Results: Thirty-four of 35 patients approached, consented to participate. Two of them did not receive their infusion due to progressive disease. 50% were female and median age was 62 (23-77). Twenty-nine patients (91%) completed baseline FACT-Lym and 20 of 21 (95%) eligible patients completed 12-month FACT-Lym. 52% completed all 4 post-baseline FACT-Lym measures. Exploratory analyses for changes in FACT-Lym scores are reported.
      Conclusion: It is feasible to measure longitudinal PROs in patients who receive CART therapy. This study will inform future studies in evaluating the patient perspective on CART therapy.
      (© 2024. The Author(s).)
    • References:
      Blood. 2017 Oct 19;130(16):1800-1808. (PMID: 28774879)
      Transplant Cell Ther. 2022 Jul;28(7):401.e1-401.e7. (PMID: 35580732)
      Blood Adv. 2020 Feb 25;4(4):629-637. (PMID: 32074277)
      Cancers (Basel). 2022 May 31;14(11):. (PMID: 35681722)
      Blood. 2017 Aug 17;130(7):859-866. (PMID: 28694324)
      Am J Prev Med. 2009 May;36(5):452-7. (PMID: 19362699)
      J Clin Oncol. 2007 Feb 10;25(5):579-86. (PMID: 17242396)
      N Engl J Med. 2019 Jan 3;380(1):45-56. (PMID: 30501490)
      N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797)
      Transplant Cell Ther. 2022 Aug;28(8):473-482. (PMID: 35550440)
      Hemasphere. 2022 Dec 01;6(12):e802. (PMID: 36504547)
      Lancet. 2020 Sep 19;396(10254):839-852. (PMID: 32888407)
      Blood. 2020 Aug 20;136(8):925-935. (PMID: 32582924)
      Cancer Med. 2021 Mar;10(6):1936-1943. (PMID: 33641257)
      Br J Cancer. 2000 Nov;83(10):1261-7. (PMID: 11044347)
      Biol Blood Marrow Transplant. 2020 Jan;26(1):34-43. (PMID: 31605820)
      J Affect Disord. 2012 Dec 10;141(2-3):343-51. (PMID: 22727334)
      Leuk Lymphoma. 2013 Sep;54(9):1942-6. (PMID: 23320888)
      Haematologica. 2022 May 01;107(5):1111-1118. (PMID: 34233446)
      Blood Adv. 2021 Apr 27;5(8):2245-2255. (PMID: 33904895)
      Eur J Haematol. 2022 Jul;109(1):3-9. (PMID: 35403753)
      Transplant Cell Ther. 2021 Nov;27(11):930.e1-930.e10. (PMID: 34265479)
      Neuro Oncol. 2021 Sep 1;23(9):1569-1575. (PMID: 33822183)
      Blood. 2022 Nov 24;140(21):2248-2260. (PMID: 35839452)
      BMJ. 2018 Apr 25;361:k1415. (PMID: 29695476)
      Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. (PMID: 30592986)
    • Contributed Indexing:
      Keywords: Chimeric antigen receptor T-cell (CART) therapy; Health-related quality of life; Large B-cell lymphoma; Patient-reported outcomes
    • الرقم المعرف:
      0 (Receptors, Chimeric Antigen)
      0 (Receptors, Antigen, T-Cell)
      Q6C9WHR03O (tisagenlecleucel)
    • الموضوع:
      Date Created: 20240809 Date Completed: 20240810 Latest Revision: 20240812
    • الموضوع:
      20240813
    • الرقم المعرف:
      PMC11312407
    • الرقم المعرف:
      10.1186/s12885-024-12574-2
    • الرقم المعرف:
      39123197